Effects of 1,25-Dihydroxy Vitamin D3 in Patients with Early Renal Failure

  • Mildred Lam
  • Francisco Llach
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 151)


Patients with chronic renal failure commonly develop secondary hyperparathyroidism as creatinine clearances decrease to less than 30 ml/min.1 However, biochemical abnormalities have also been noted in patients with early renal failure (ERF), with higher creatinine clearances (30 to 90 ml/min). These abnormalities include hypocalcemia, hypophosphatemia, and elevated serum levels of parathyroid hormone (PTH).2-4 Such abnormalities indicate that secondary hyperparathyroidism may be present even in the early stages of chronic renal failure.


Chronic Renal Failure Secondary Hyperparathyroidism Serum Phosphate Urinary Phosphate Excretion Sodium Potassium Phosphate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arnaud CD: Hyperparathyroidism and renal failure. Kidney Int 4:89–95, 1973.PubMedCrossRefGoogle Scholar
  2. 2.
    Reiss E, Canterbury JM, Bilinsky RT: Measurement of serum parathyroid hormone in renal insufficiency. Trans Assn Am Phys 81:104–114, 1968.Google Scholar
  3. 3.
    Massry SG, Coburn JW, Lee DBN, Jowsey J, Kleeman CR: Skeletal resistance to parathyroid hormone in renal failure: studies in 105 human subjects. Ann Intern Med 78:357–364, 1973.PubMedGoogle Scholar
  4. 4.
    Coburn JW, Koppel MH, Brickman AS, Massry SG: Study of intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 3:264–272, 1973.PubMedCrossRefGoogle Scholar
  5. 5.
    Massry SG, Ritz E: The pathogenesis of secondary hyperparathyroidism of renal failure: Is there a controversy? Arch Intern Med 138:853–856, 1978.PubMedCrossRefGoogle Scholar
  6. 6.
    Tessitore N, Lund BJ, Bonucci B, Sorenson E, Maschio OH: unpublished data.Google Scholar
  7. 7.
    Brickman AS, Coburn JW, Sherrard DJ, Wong EGC, Norman AW, Singer FR: Clinical effects of 1,25-dihydroxyvitamin D3 in uremic patients with overt osteodystrophy. Contrib Nephrol 18:29–41, 1980.PubMedGoogle Scholar
  8. 8.
    Berl T, Berns AS, Huffer WE, Alfrey AC, Arnaud CD, Schrier RW: Controlled trial of the effects of 1,25-dihydroxycholecalciferol in patients treated with regular dialysis. Contrib Nephrol 18:72–81, 1980.PubMedGoogle Scholar
  9. 9.
    Goldstein DA, Malluche HH, Massry SG: Long-term effects of 1,25(OH)2D3 on clinical and biochemical derangements of divalent ions in dialysis patients. Contrib Nephrol 18:42–54, 1980.PubMedGoogle Scholar
  10. 10.
    Sherrard DJ, Coburn JW, Brickman AS, Singer FR, Maloney N: Skeletal response to treatment with 1,25-dihydroxyvitamin D in renal failure. Contrib Nephrol 18:92–97, 1980.PubMedGoogle Scholar
  11. 11.
    Walton RJ, Bijvoet OL: Nomogram for derivation of renal threshold phosphate concentration. Lancet 2:309–310, 1975.PubMedCrossRefGoogle Scholar
  12. 12.
    Mayer GP, Hurst JG, Barto JA, Keaton JA, Moore MP: Effect of epinephrine on parathyroid hormone secretion in calves. Endocrinology 104:1181–1187, 1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Bricker NS, Slatopolsky E, Reiss E, Avioli LV: Calcium, phosphorus, and bone in renal disease and transplantation. Arch Intern Med 123:543–553, 1969.PubMedCrossRefGoogle Scholar
  14. 14.
    Llach F, Massry SG, Singer FR, Kurokawa K, Kaye JH, Coburn JW: Skeletal resistance to endogenous parathyroid hormone in patients with early renal failure: A possible cause for secondary hyperparathyroidism. J Clin Endocrinol Metab 41:339–345, 1975.PubMedCrossRefGoogle Scholar
  15. 15.
    Slatopolsky E, Gray R, Adams ND, Lewis J, Hruska K, Martin K, Klahr S, DeLuca H, Lemann J: Low serum levels of 1,25-dihydroxycholecalciferol are not responsible for the development of secondary hyperparathyroidism in early renal failure (abstract). Kidney Int 14:733, 1978.Google Scholar
  16. 16.
    Tanaka Y, DeLuca HF, Omdahl J, Holick MF: Mechanism of action of 1,25-dihydroxycholecalciferol on intestinal calcium transport. Proc Natl Acad Sci USA 68:1286–1288, 1971.PubMedCrossRefGoogle Scholar
  17. 17.
    Metz SA, Baylink DJ, Hughes MR, Haussler MR, Robertson RP: Osseous resistance to parathyroid hormone due to 1,25-dihydroxycholecalciferol deficiency. N Engl J Med 297:1084–1090, 1977.PubMedCrossRefGoogle Scholar
  18. 18.
    Llach F, Massry SG, Koffler A, Malluche HH, Singer FR, Brickman AS, Kurokawa K: Secondary hyperparathyroidism in early renal failure: Role of phosphate retention (abstract). Kidney Int 12:459, 1977.Google Scholar
  19. 19.
    Healy MD, Malluche HH, Goldstein DA, Singer FR, Massry SG: Effects of longterm therapy with calcitriol in patients with moderate renal failure. Arch Intern Med 140:1030–1033, 1980.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • Mildred Lam
    • 1
    • 2
  • Francisco Llach
    • 1
    • 2
  1. 1.University of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Veterans Administration HospitalOklahoma CityUSA

Personalised recommendations